Abstract
Chronic hepatitis B virus (HBV) infection can cause chronic hepatitis, cirrhosis, liver failure, and hepatocellular carcinoma (HCC). Chronic hepatitis B is characterized by an early replicative phase with hepatitis B e antigen (HBeAg) positivity, high serum HBV-DNA levels and disease activity (HBeAgpositive chronic hepatitis), and a late inactive phase with anti-HBe seroconversion, low or undetectable serum HBV-DNA, and liver disease remission (inactive carrier state). Another form is characterized by active disease due to HBV variants not expressing HBeAg (HBeAg-negative chronic hepatitis). Both types of chronic hepatitis B can lead to cirrhosis and its complications. The incidence of cirrhosis is two to five per 100 person-years, but may be as high as eight to 10 in HBeAg-negative cases. The incidence of HCC varies geographically and increases with the duration and severity of liver disease (0.1 to 8 per 100 person-years). The prognosis is reasonably good in compensated cirrhosis, but very poor following decompensation. Viral and environmental factors influence the natural history of chronic hepatitis B and explain the heterogeneity of its clinical outcomes.
Similar content being viewed by others
References and Recommended Reading
EASL Jury: EASL International Consensus Conference on Hepatitis B. 13–14 September, 2002: Geneva, Switzerland. Consensus statement (short version). J Hepatol 2003, 38:533–540. The main conclusion of the most recent International Consensus Conference on the management of hepatitis B.
Lok AS, Heathcote EJ, Hoofnagle JH: Management of hepatitis B: 2000—summary of a workshop. Gastroenterology 2001, 120:1828–1853. Detailed summary of the National Institutes of Health 2000 workshop on the management of hepatitis B.
Lok AS, McMahon BJ: Chronic hepatitis B. Hepatology 2001, 34:1225–1241. A comprehensive review on the different virologic and clinical aspects of chronic hepatitis B.
Chang MH: Natural history of hepatitis B infection in children. J Gastroenterol Hepatol 2000, 15(suppl):E11-E19.
Fattovich G: Natural history and prognosis of hepatitis B. Semin Liver Dis 2003, 23:47–58.
Bortolotti F, Jara P, Crivellaro C, et al.: Outcome of chronic hepatitis B in Caucasian children during a 20-year observation period. J Hepatol 1998, 29:184–190.
Fattovich G, Rugge M, Brollo L, et al.: Clinical, virologic and histologic outcome following seroconversion from HBeAg to anti-HBe in chronic hepatitis type B. Hepatology 1986, 6:167–172.
Hsu YS, Chien RN, Yeh CT, et al.: Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology 2002, 35:1522–1527.
McMahon BJ, Holck P, Bulkow L, Snowball M: Serologic and clinical outcomes of 1536 Alaska natives chronically infected with hepatitis B virus. Ann Intern Med 2001, 135:759–768. An updated review article on the clinical outcomes and prognostic markers of hepatitis B.
Yuen MF, Yuan HJ, Hui CK, et al.: A large population study of spontaneous HBeAg seroconversion and acute exacerbation of chronic hepatitis B infection: implications for antiviral therapy. Gut 2003, 52:416–419.
Alward WL, McMahon BJ, Hall DB, et al.: The long-term serological course of asymptomatic hepatitis B virus carriers and the development of primary hepatocellular carcinoma. J Infect Dis 1985, 151:604–609.
Liaw YF: Hepatitis flares and hepatitis B e antigen seroconversion: implication in anti-hepatitis B virus therapy. J Gastroenterol Hepatol 2003, 18:246–252.
Chu CJ, Hussain M, Lok AS: Hepatitis B virus genotype B is associated with earlier HBeAg seroconversion compared to hepatitis B virus genotype C. Gastroenterology 2002, 122:1756–1762.
Yuen MF, Sablon E, Yuan HJ, et al.: Significance of hepatitis B genotype in acute exacerbation, HBeAg seroconversion, cirrhosis-related complications, and hepatocellular carcinoma. Hepatology 2003, 37:562–567.
Sanchez-Tapias JM, Costa J, Mas A, et al.: Influence of hepatitis B virus genotype on the long-term outcome of chronic hepatitis B in Western patients. Gastroenterology 2002, 123:1848–1856.
Hadziyannis SJ, Vassilopoulos D: Hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2001, 34:617–624.
Funk ML, Rosenberg DM, Lok AS: World-wide epidemiology of HBeAg-negative chronic hepatitis B and associated precore and core promoter variants. J Viral Hepat 2002, 9:52–61.
Brunetto MR, Oliveri F, Coco B, et al.: Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study. J Hepatol 2002, 36:263–270.
Papatheodoridis GV, Manesis E, Hadziyannis SJ: The long-term outcome of interferon-alpha treated and untreated patients with HBeAg-negative chronic hepatitis B. J Hepatol 2001, 34:306–313.
Perillo RP: Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease. Gastroenterology 2001, 120:1009–1022.
Fattovich G, Giustina G, Sanchez-Tapias J, et al.: Delayed clearance of serum HBsAg in compensated cirrhosis B: relation to interferon alpha therapy and disease prognosis. Am J Gastroenterol 1998, 93:896–900.
Liaw YF, Sheen IS, Chen TJ, et al.: Incidence, determinants and significance of delayed clearance of serum HBsAg in chronic hepatitis B virus infection: a prospective study. Hepatology 1991, 13:627–631.
Chen YC, Sheen IS, Chu CM, Liaw YF: Prognosis following spontaneous HBsAg seroclearance in chronic hepatitis B patients with or without concurrent infection. Gastroenterology 2002, 123:1084–1089.
Fattovich G, Brollo L, Giustina G, et al.: Natural history and prognostic factors of chronic hepatitis type B. Gut 1991, 32:294–298.
Ikeda K, Saitoh S, Suzuki Y, et al.: Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis: a prospective observation in 2215 patients. J Hepatol 1998, 28:930–938.
Fattovich G, Brollo L, Alberti A, et al.: Long-term follow-up of anti-HBe positive chronic active hepatitis B. Hepatology 1988, 8:1651–1654.
Brunetto MR, Oliveri F, Rocca G, et al.: Natural course and response to interferon of chronic hepatitis B accompanied by antibody to hepatitis B e antigen. Hepatology 1989, 10:198–202.
Bortolotti F, Calzia R, Cadrobbi P, et al.: Liver cirrhosis associated with chronic hepatitis B virus infection in childhood. J Pediatr 1986, 108:224–227.
Realdi G, Fattovich G, Hadziyannis S, et al.: Survival and prognostic factors in 366 patients with compensated cirrhosis type B: a multicenter study. J Hepatol 1994, 21:656–666.
Bosh FX, Ribes J, Borras J: Epidemiology of primary liver cancer. Semin Liver Dis 1999, 19:271–285.
Beasley RP: Hepatitis B virus. The major etiology of hepatocellular carcinoma. Cancer 1988, 61:1942–1956.
Chang MH, Chen CJ, Lai MS, et al.: Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med 1997, 336:1906–1907.
Liaw YF, Lin DY, Chen TJ, Chu CM: Natural course after the development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Liver 1989, 9:235–241.
Oon CJ: Long-term survival following treatment of hepatocellular carcinoma in Singapore: evaluation of Wellferon in the prophylaxis of high-risk pre-cancerous conditions. Cancer Chemother Pharmacol 1992, 31(suppl 1):S137-S142.
Fattovich G, Pantalena M, Zagni I, et al.: Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: a cohort study of 297 patients. Am J Gastroenterol 2002, 97:2886–2895.
Chung HT, Lai CL, Lok AS: Pathogenic role of hepatitis B virus in hepatitis B surface antigen-negative decompensated cirrhosis. Hepatology 1995, 22:25–29.
Di Marco V, Lo Iacono O, Cammà C, et al.: The long-term course of chronic hepatitis B. Hepatology 1999, 30:257–264.
De Franchis R, Meucci G, Vecchi M, et al.: The natural history of asymptomatic hepatitis B surface antigen carriers. Ann Intern Med 1993, 118:191–194.
Bellentani S, Dal Molin G, Miglioli L, et al.: Natural history of HBV infection: a 9 year follow-up of the Dionysos cohort. J Hepatol 2002, 36(suppl 1):228.
De Jongh FE, Janssen HLA, De Man RA, et al.: Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver. Gastroenterology 1992, 103:1630–1635.
Fattovich G, Giustina G, Schalm SW, et al.: Occurrence of hepatocellular carcinoma and decompensation in Western European patients with cirrhosis type B. Hepatology 1995, 21:77–82.
Liaw YF, Tai DI, Chu CM, Chen TJ: The development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Hepatology 1988, 8:493–496.
Fattovich G, Giustina G, Realdi G, et al.: Long-term outcome of hepatitis B e antigen-positive patients with compensated cirrhosis treated with interferon alfa. Hepatology 1997, 26:1338–1342.
Yang HI, Lu SN, Liaw YF, et al.: Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med 2002, 347:168–174.
Kao JH: Hepatitis B viral genotypes: clinical relevance and molecular characteristics. J Gastroenterol Hepatol 2002, 17:643–650.
Kao JH, Chen PJ, Lai MY, Chen DS: Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B. Gastroenterology 2000, 118:554–559.
Sumi H, Yokosuka O, Seki N, et al.: Influence of hepatitis B virus genotypes on the progression of chronic liver disease. Hepatology 2003, 37:19–26.
Liaw YF: Role of hepatitis C virus in dual and triple hepatitis virus infection. Hepatology 1995, 22:1101–1108.
Fattovich G, Boscaro S, Noventa F, et al.: Influence of hepatitis delta virus infection on progression to cirrhosis in chronic hepatitis type B. J Infect Dis 1987, 155:931–935.
Rosina F, Conoscitore P, Cuppone R, et al.: Changing pattern of chronic hepatitis D in Southern Europe. Gastroenterology 1999, 117:161–166.
Fattovich G, Giustina G, Christensen E, et al.: Influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type B. Gut 2000, 46:420–426.
Benvegnú L, Fattovich G, Noventa F, et al.: Concurrent hepatitis B and C virus infection and risk of hepatocellular carcinoma in cirrhosis. Cancer 1994, 74:2442–2448.
Tsai JF, Jeng JE, Ho MS, et al.: Effect of hepatitis C and B virus infection on risk of hepatocellular carcinoma: a prospective study. Br J Cancer 1997, 76:968–974.
Di Martino V, Thevenot T, Colin JF, et al.: Influence of HIV infection on the response to interferon therapy and the longterm outcome of chronic hepatitis B. Gastroenterology 2002, 123:1812–1822.
Poynard T, Mathurin P, Lai CL, et al.: A comparison of fibrosis progression in chronic liver diseases. J Hepatol 2003, 38:257–265.
Donato F, Tagger A, Gelatti U, et al.: Alcohol and hepatocellular carcinoma: the effect of lifetime intake and hepatitis virus infections in men and women. Am J Epidemiol 2002, 155:323–331.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Alberti, A., Fattovich, G. Natural history of chronic hepatitis B. Curr hepatitis rep 3, 54–60 (2004). https://doi.org/10.1007/s11901-004-0010-0
Issue Date:
DOI: https://doi.org/10.1007/s11901-004-0010-0